Article
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2024
Singh Harshabad, Sahgal Pranshu, Kapner Kevin, Corsello Steven M, Gupta Hersh, Gujrathi Rahul, Li Yvonne Y, Cherniack Andrew D, El Alam Raquelle, Kerfoot Joseph, Andrews Elizabeth, Lee Annette, Nambiar Chetan, Hannigan Alison M, Remland Joshua, Brais Lauren, Leahy Meghan E, Rubinson Douglas A, Schlechter Benjamin L, Meyerson Matthew, Kuang Yanan, Paweletz Cloud P, Lee Jessica K, Quintanilha Julia C F, Aguirre Andrew J, Perez Kimberly J, Huffman Brandon M, Rossi Humberto, Abrams Thomas A, Kabraji Sheheryar, Trusolino Livio, Bertotti Andrea, Sicinska Ewa T, Parikh Aparna R, Wolpin Brian M, Schrock Alexa B, Giannakis Marios, Ng Kimmie, Meyerhardt Jeffrey A, Hornick Jason L, Sethi Nilay S, Cleary James M
Abstract excerpt
PURPOSE: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. EXPERIMENTAL DESIGN: Dana-Farber and Foundation Medicine Inc. Colorectal cancer cohorts with genomic profiling were used to identify ERBB2-amplified cases [Dana-Farber, n = 47/2,729 (1.7%); FMI, n = 1857/49,839 (3.7%)]. Outcomes of patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.